June 27, 2024 03:31 PM EDTUpdated 04:27 PM

What Coherus' $40M sale of its Humira biosimilar says about the crowded market

Zachary Brennan

Senior Editor

Coherus BioSciences is selling its Humira biosimilar for just $40 million, only three years after it won FDA approval, showing just how crowded the market …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

What Coherus' $40M sale of its Humira biosimilar says about the crowded market

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

Immunology biotech Alumis secures $250M in shrunken IPO

What Co­herus' $40M sale of its Hu­mi­ra biosim­i­lar says about the crowd­ed mar­ket

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

What Coherus' $40M sale of its Humira biosimilar says about the crowded market

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

Immunology biotech Alumis secures $250M in shrunken IPO